Telix Annual General Meeting - Chairman and CEO Addresses
Filed with ASX · · 6 pages · English
Telix Pharmaceuticals Limited on 6ix
In the deck
Story so far
Earlier from Telix Pharmaceuticals
- Telix Completes Proof-of-Concept Study for Alpha Therapy
- Telix has Filed Registration Statement for Proposed US IPO
- Telix Reports Q1 2024 Financial Performance
- Telix Completes Acquisition of QSAM
- Telix Q1 2024 Revenue and Business Update
Later from Telix Pharmaceuticals
- Telix Annual General Meeting - Presentation
- Telix Submits NDA for New Prostate Cancer Imaging Agent
- Response to ASX Query
- ProstACT SELECT Study of TLX591 rADC Therapy - Positive rPFS
- Telix Completes TLX250-CDx (Zircaix) BLA Submission
Follow Telix Pharmaceuticals into a list and get an email when it puts out news.
Follow Telix Pharmaceuticals